Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Receivables - OtherRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

MBX Biosciences (MBX) Other Non-Current Assets (2023 - 2026)

MBX Biosciences has reported Other Non-Current Assets over the past 4 years, most recently at $42000.0 for Q1 2026.

  • Quarterly results put Other Non-Current Assets at $42000.0 for Q1 2026, down 16.0% from a year ago — trailing twelve months through Mar 2026 was $42000.0 (down 16.0% YoY), and the annual figure for FY2023 was $50000.0, changed.
  • Other Non-Current Assets reached $42000.0 in Q1 2026 per MBX's latest filing, down from $50000.0 in the prior quarter.
  • Across five years, Other Non-Current Assets topped out at $50000.0 in Q4 2023 and bottomed at $42000.0 in Q1 2026.
  • Median Other Non-Current Assets over the past 4 years was $50000.0 (2023), compared with a mean of $48666.7.
  • The largest annual shift saw Other Non-Current Assets changed 0.0% in 2025 before it fell 16.0% in 2026.
  • Over 4 years, Other Non-Current Assets stood at $50000.0 in 2023, then changed by 0.0% to $50000.0 in 2024, then changed by 0.0% to $50000.0 in 2025, then dropped by 16.0% to $42000.0 in 2026.
  • Business Quant data shows Other Non-Current Assets for MBX at $42000.0 in Q1 2026, $50000.0 in Q3 2025, and $50000.0 in Q2 2025.